INS and Hyperglycemia: AAV-Hnf1α-mediated gene therapy prevented the development of hyperglycemia, hyperinsulinemia, increased glucose tolerance, and enhanced insulin secretion by the pancreatic islet apparatus, thereby reversing MODY3 in rodents.